MUSTO, Pellegrino
 Distribuzione geografica
Continente #
NA - Nord America 6.325
EU - Europa 2.388
AS - Asia 1.108
SA - Sud America 629
AF - Africa 25
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 10.477
Nazione #
US - Stati Uniti d'America 6.276
RU - Federazione Russa 676
BR - Brasile 582
SE - Svezia 537
SG - Singapore 523
IT - Italia 403
CN - Cina 317
DE - Germania 209
GB - Regno Unito 204
FR - Francia 140
HK - Hong Kong 106
FI - Finlandia 72
ID - Indonesia 46
AT - Austria 28
IE - Irlanda 28
CA - Canada 26
UA - Ucraina 21
TR - Turchia 17
VN - Vietnam 17
IN - India 16
BE - Belgio 15
NL - Olanda 15
AR - Argentina 13
CZ - Repubblica Ceca 13
MX - Messico 13
EC - Ecuador 9
BD - Bangladesh 7
IQ - Iraq 7
LT - Lituania 6
VE - Venezuela 6
JP - Giappone 5
MA - Marocco 5
PE - Perù 5
PY - Paraguay 5
UZ - Uzbekistan 5
AZ - Azerbaigian 4
CO - Colombia 4
DO - Repubblica Dominicana 4
IL - Israele 4
KE - Kenya 4
PK - Pakistan 4
PL - Polonia 4
TW - Taiwan 4
AL - Albania 3
CL - Cile 3
EG - Egitto 3
JM - Giamaica 3
JO - Giordania 3
KR - Corea 3
LV - Lettonia 3
SN - Senegal 3
TN - Tunisia 3
ZA - Sudafrica 3
BO - Bolivia 2
DZ - Algeria 2
KG - Kirghizistan 2
NP - Nepal 2
OM - Oman 2
PA - Panama 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BY - Bielorussia 1
CH - Svizzera 1
EE - Estonia 1
ES - Italia 1
GE - Georgia 1
GR - Grecia 1
IR - Iran 1
KH - Cambogia 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
NG - Nigeria 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
PH - Filippine 1
PS - Palestinian Territory 1
RS - Serbia 1
SA - Arabia Saudita 1
SY - Repubblica araba siriana 1
UG - Uganda 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 10.477
Città #
Fairfield 1.072
Nyköping 453
New York 405
Chandler 394
Woodbridge 393
Ashburn 363
Houston 343
Lawrence 342
Singapore 340
Cambridge 337
Seattle 331
Wilmington 288
Roxbury 284
Des Moines 235
Ann Arbor 217
San Diego 126
Paris 107
Hong Kong 82
Princeton 77
Santa Clara 75
Bari 69
London 66
Helsinki 52
Matera 48
Jakarta 45
Inglewood 43
Nuremberg 43
Jacksonville 41
Milan 40
Moscow 40
Boardman 37
São Paulo 37
Beijing 35
Potenza 31
Dublin 28
Nanjing 27
Guangzhou 25
Los Angeles 23
Shanghai 22
Falkenstein 21
Frankfurt am Main 21
Kilburn 20
Hounslow 19
Norwalk 18
Rome 18
Rio de Janeiro 16
Brussels 15
Avigliano 14
Belo Horizonte 14
Dong Ket 14
Brasília 12
Chiswick 12
Jiaxing 12
Shenyang 12
Verdellino 11
Vienna 11
Wuhan 11
Campinas 10
Munich 10
Ribeirão Preto 10
Salvador 10
Brooklyn 9
Prescot 9
Hanover 8
New Bedfont 8
Ottawa 8
Porto Alegre 8
Brno 7
Dearborn 7
Goiânia 7
Guarulhos 7
Imbersago 7
Lauterbourg 7
Toronto 7
Curitiba 6
Düsseldorf 6
Istanbul 6
Juiz de Fora 6
Marseille 6
Nanchang 6
Portsmouth 6
Quanzhou 6
Shenzhen 6
Waterloo 6
Bitetto 5
Carapicuíba 5
Duque de Caxias 5
Messina 5
Mexico City 5
Modugno 5
Sorocaba 5
Southwark 5
Tashkent 5
Torino 5
Washington 5
Alcamo 4
Aracaju 4
Baku 4
Betim 4
Bitonto 4
Totale 7.561
Nome #
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial 143
Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets 130
Differences among young adults, adults, and elderly chronic myeloid leukemia patients. 114
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma 112
Amyloid in bone marrow smears of patients affected by multiple myeloma 108
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 106
Cardiovascular events and intensity of treatment in polycythemia vera. 103
null 101
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial 97
Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM) 96
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis 95
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis 94
Global methylation patterns in primary plasma cell leukemia 88
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis 87
FISH analysis reveals frequent co-occurrence of 4q24/TET2 and 5q and/or 7q deletions. 85
null 85
Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response 85
null 82
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors. 79
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia 79
Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts 79
Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study) 77
90y-ibritumomab tiuxetan as consolidation therapy after autologous stem cell trasplantation in aggressive non-Hodgkin lymphoma 77
Observational study of chronic myeloid leukemia italian patients who discontinued tyrosine kinase inhibitors in clinical practice 77
null 75
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study 73
Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma 73
null 71
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial 65
Different spatial distribution of inflammatory cells in the tumor microenvironment of ABC and GBC subgroups of diffuse large B cell lymphoma 64
DARA-VD VERSUS DARA-RD AS SALVAGE THERAPY FOR PATIENTS WITH MYELOMA. INITIAL FOLLOW-UP OF AN ITALIAN MULTICENTER RETROSPECTIVE CLINICAL EXPERIENCE BY RETE EMATOLOGICA PUGLIESE 60
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: Updated follow-up and improved survival 58
Surface endoglin (CD105) expression on acute leukemia blast cells: an extensive flow cytometry study of 1002 patients 57
Deferasirox drives ROS-mediated differentiation and induces interferon-stimulated gene expression in human healthy haematopoietic stem/progenitor cells and in leukemia cells 56
RUNX1 gene alterations characterized by allelic preference in adult acute myeloid leukemia 56
Epitranscriptomics in normal and malignant hematopoiesis 55
Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine—Results from the Italian ‘Back to Life’ project 54
REAL-WORLD ITALIAN EXPERIENCE OF POMALIDOMIDE IN RELAPSED-REFRACTORY MYELOMA: RETROSPECTIVE MULTICENTER STUDY BY THE RETE EMATOLOGICA PUGLIESE AND BASILICATA 53
SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma 53
Myeloma cells regulate miRNA transfer from fibroblast-derived exosomes by expression of lncRNAs 53
A reduced intensity conditioning regimen for allografting following autografting is feasible and has strong anti-myeloma activity 52
Inflammatory Cells in Diffuse Large B Cell Lymphoma 52
A Pyrazolo[3,4-d]pyrimidine compound inhibits Fyn phosphorylation and induces apoptosis in natural killer cell leukemia. 49
Nanopore sequencing approach for immunoglobulin gene analysis in chronic lymphocytic leukemia 49
Bortezomib and zoledornic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma 47
null 46
"Hemolysis, or not hemolysis, that is the question". Use of hydroxychloroquine in a patient with COVID-19 infection and G6PD deficiency 46
After Treatment Decrease of Bone Marrow Tregs and Outcome in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia 46
SARS-CoV-2 Infection Incidence and Outcome Before and After Full Vaccination in Patients With Monoclonal Gammopathy of Undetermined Significance 45
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 45
IRF4 expression is low in Philadelphia negative myeloproliferative neoplasms and is associated with a worse prognosis 45
Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia 44
Analysis of amount, size, protein phenotype and molecular content of circulating extracellular vesicles identifies new biomarkers in multiple myeloma 44
Features, reason for testing, and changes with time of 583 paroxysmal nocturnal hemoglobinuria clones from 529 patients: a multicenter Italian study 44
Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: A pooled analysis of two studies 44
Drug-related side effects after rituximab infusion in patients with chronic lymphocytic leukemia 43
A comparative analysis of biosimilar vs originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma; a propensity-score weighted multicenter approach. 43
90Y-ibritumomab tiuxetan as consolidation therapy after autologous stem cell transplantation in aggressive non-Hodgkin lymphoma 43
Serological response following BNT162b2 anti-SARS-CoV-2 mRNA vaccination in haematopoietic stem cell transplantation patients 43
The Effect of the Tumor Microenvironment on Lymphoid Neoplasms Derived from B Cells 43
Can the new and old drugs exert an immunomodulatory effect in acute myeloid leukemia? 42
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials 41
A pilot characterization of human lung NSCLC by protein pathway activation mapping 41
What Is New in the Treatment of Smoldering Multiple Myeloma? 41
F-18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma 40
A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias 40
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease 40
CD200 and prognosis in chronic lymphocytic leukemia: Conflicting results 40
FLT3 mutational analysis in acute myeloid leukemia: Advantages and pitfalls with different approaches 40
Clonal Hematopoiesis at the Crossroads of Inflammatory Bowel Diseases and Hematological Malignancies: A Biological Link? 39
A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia 39
Achievement of European standards by CROB-IRCCS 39
Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice 39
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study 39
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies 38
A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant 38
Gastric normal adjacent mucosa versus healthy and cancer tissues: Distinctive transcriptomic profiles and biological features 37
Iron Toxicity and Chelation Therapy in Hematopoietic Stem Cell Transplant 37
Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study 36
Superiority of droplet digital PCR over real-time quantitative PCR for JAK2 V617F allele mutational burden assessment in myeloproliferative neoplasms: A retrospective study 36
P077 Adaptation and changes in quality of life in patients with myelodysplastic syndrome 36
New treatment strategies for elderly myeloma patients 36
CD200 included in a 4-marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia 36
P138 Valproic acid at therapeutic plasma levels may increase 5-azacitidine efficacy in higher risk myelodysplastic syndromes 35
Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+) 35
Acquired hemophilia a successfully treated with rituximab 34
Advanced mast cell disease: an Italian Hematological Multicenter experience 34
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 34
Tumor cell microenvironment and microvessel density analysis in MALT type lymphoma 34
Incidence and outcome of SARS-CoV-2 infection in patients with monoclonal gammopathy of undetermined significance: a case-control study 33
A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma 33
Immunomodulatory drugs in acute myeloid leukemia treatment 33
An update on biology, diagnosis and treatment of primary plasma cell leukemia 33
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: A pooled analysis of two randomized trials 33
Future in the past: Azorella glabra wedd. as a source of new natural compounds with antiproliferative and cytotoxic activity on multiple myeloma cells 33
Dysregulation of mirna in leukemia: Exploiting mirna expression profiles as biomarkers 32
Meningeal Involvement in Primary Plasma Cell Leukemia 32
Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor 32
Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: A pooled analysis of two phase i/ii studies 31
A case of acute promyelocytic leukemia variant with derivative chromosome 3 der(3)t(3;8) associated with 8q partial gain 31
Totale 5.620
Categoria #
all - tutte 114.115
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 114.115


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202070 0 0 0 0 0 0 0 0 0 0 38 32
2020/20211.463 19 42 17 38 71 53 46 62 23 67 984 41
2021/20222.498 536 283 17 35 20 291 110 85 244 196 287 394
2022/20231.717 404 234 142 66 102 192 111 142 232 18 46 28
2023/20241.196 97 139 78 56 102 460 57 28 2 14 22 141
2024/20253.206 158 25 399 102 152 616 543 425 340 384 62 0
Totale 11.288